Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate safety and tolerability of repeated ascending oral
doses of 4SC-205 in patients with advanced and incurable solid tumors or malignant lymphomas.